SHANGHAI OPM BIOSCIENCES CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.81 CNY | +2.77% |
|
+13.37% | -31.47% |
| Sales 2024 * | 358M 49.37M 67.58M | Sales 2025 * | 504M 69.65M 95.34M | Capitalization | 4.34B 599M 820M |
|---|---|---|---|---|---|
| Net income 2024 * | 93M 12.84M 17.58M | Net income 2025 * | 167M 23.06M 31.57M | EV / Sales 2024 * | 12.1 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 8.6 x |
| P/E ratio 2024 * |
46.4
x | P/E ratio 2025 * |
26
x | Employees | 261 |
| Yield 2024 * |
0.05% | Yield 2025 * |
0.11% | Free-Float | 25.54% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.77% | ||
| 1 week | +13.37% | ||
| 1 month | +2.44% | ||
| 3 months | +5.06% | ||
| 6 months | -29.18% | ||
| Current year | -31.47% |
1 week
33.70
38.26
1 month
29.6738.48
Current year
29.6756.08
1 year
29.6764.64
3 years
29.6798.56
5 years
29.6798.56
10 years
29.6798.56
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Hua Xiao
CEO | Chief Executive Officer | 50 | 13-11-26 |
Liang Ping Ni
DFI | Director of Finance/CFO | 40 | 19-04-30 |
Chuan Yang Guo
BRD | Director/Board Member | 36 | 14-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jiang Feng Li
BRD | Director/Board Member | 47 | 20-08-11 |
Zhi Hua Xiao
CEO | Chief Executive Officer | 50 | 13-11-26 |
Jun Jie Zhang
BRD | Director/Board Member | 47 | 20-10-13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 37.81 | +2.77% | 1,493,319 |
| 24-04-29 | 36.79 | +10.31% | 1,150,632 |
| 24-04-26 | 33.35 | +2.68% | 714,115 |
| 24-04-25 | 32.48 | +1.44% | 833,976 |
End-of-day quote Shanghai S.E., April 29, 2024
More quotes
Shanghai Aopu Biotechnology Co Ltd is a China-based company mainly provides cell culture medium products and services. The Company's cell culture medium products are widely used in the manufacturing of protein, antibiotics, vaccine, cell therapy products, gene therapy products, and other biological products. The Company's contract development and manufacturing organization (CDMO) service platform provides comprehensive services covering antibody engineering humanized screening, cell strain cultivation, process development, pilot scale production, and clinical-stage sample production. The Company conducts businesses both in the domestic market and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
37.81
CNY
Average target price
58.66
CNY
Spread / Average Target
+55.14%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -31.47% | 600M | |
| -3.79% | 88.14B | |
| +1.45% | 40.51B | |
| -15.94% | 31.67B | |
| +52.66% | 24.62B | |
| -14.50% | 15.65B | |
| -9.12% | 11.97B | |
| -14.38% | 12.07B | |
| -42.56% | 11.61B | |
| +4.87% | 8.81B |
- Stock Market
- Equities
- 688293 Stock
